(Ivanhoe Newswire) -- Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer, according to an international research study. It’s the first to document reduced fracture risk in men receiving the hormone-blocking treatment.
